Timis Tanase, Bergthorsson Jon Thor, Greiff Victor, Cenariu Mihai, Cenariu Diana
Department of Oncology, Bistrita Emergency Hospital, 420094 Bistrita, Romania.
Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.
Curr Issues Mol Biol. 2023 Jun 30;45(7):5575-5597. doi: 10.3390/cimb45070352.
Almost every death in young patients with an advanced skin tumor is caused by melanoma. Today, with the help of modern treatments, these patients survive longer or can even achieve a cure. Advanced stage melanoma is frequently related with poor prognosis and physicians still find this disease difficult to manage due to the absence of a lasting response to initial treatment regimens and the lack of randomized clinical trials in post immunotherapy/targeted molecular therapy settings. New therapeutic targets are emerging from preclinical data on the genetic profile of melanocytes and from the identification of molecular factors involved in the pathogenesis of malignant transformation. In the current paper, we present the diagnostic challenges, molecular biology and genetics of malignant melanoma, as well as the current therapeutic options for patients with this diagnosis.
几乎每一例晚期皮肤肿瘤年轻患者的死亡都是由黑色素瘤引起的。如今,在现代治疗手段的帮助下,这些患者存活时间更长,甚至能够治愈。晚期黑色素瘤通常预后较差,由于对初始治疗方案缺乏持久反应以及免疫治疗/靶向分子治疗后缺乏随机临床试验,医生们仍然觉得这种疾病难以处理。关于黑素细胞基因图谱的临床前数据以及对参与恶性转化发病机制的分子因素的识别,正在催生出新的治疗靶点。在本文中,我们介绍了恶性黑色素瘤的诊断挑战、分子生物学和遗传学,以及针对该诊断患者的当前治疗选择。